gene in individuals relapsing following procedure with the BCL2 antagonist venetoclax. sixty six Resistance to those brokers has been related to these mutations in close to 70% of cases, Though they usually are subclonal and their unique purpose triggering resistance has to be verified.Over the past many years, the number of individuals referred fo